Dr. San Miguel presented interim data on the ongoing PETHEMA study of melphalan, prednisone, and Velcade in elderly, previously untreated myeloma patients
Dr. Vij addressed the increased incidence of herpes zoster (shingles) with Velcade in the peri-transplant setting and preventative measures that can be taken to avoid this complication
Dr. Ludwig presented an interim analysis of an ongoing trial of thal/dex versus MP in 205 elderly (median age 72), newly diagnosed patients with myeloma
Dr. Facon reports on an interim analysis of the ongoing Intergroup Francais du Myelome (IFN) 99-06 clinical trial comparing melphalan–prednisone (MP), melphalan-prednisone-thalidomide (MPT), and stem cell transplant with reduced-dose-chemotherapy (melphalan 100 mg/m2 or “mel 100”) in elderly (65-75 years of age), newly diagnosed myeloma patients
Dr. Dispenzieri presented data on a pre-clinical mouse study with the combination of Velcade and the radiopharmaceutical Quadramet (153 samarium EDTMP)
Dr. San Miguel presented preliminary data from a Phase I/II study in patients with relapsed/refractory myeloma of the novel therapy Aplidin, which is a marine-derived molecule with a novel mechanism of action
Dr. Wang presented data on a Phase I dose escalation multi-center clinical trial with the new drug Atiprimod for patients with relapsed/refractory myeloma
Dr. McGuirk reported on the first 70 patients enrolled in the AMD-3100 compassionate use program for poor stem cell mobilizers in need of stem cell harvest prior to autologous stem cell transplantation (SCT)
Dr. Van Ness presented his current work with the IMF Bank On A Cure program’s genetic data along with information about current and future research being conducted by the Bank On A Cure Team
Dr. Sonneveld studied single nucleotide polymorphisms (SNPs) collected from patient tissue samples in a large, multi-center, randomized, single versus double autologous transplant clinical trial
Dr. Ludwig presented an analysis of clinical features and outcomes in 259 myeloma patients younger than 40 years versus 8,296 patients older than 40 years
Dr. Fonseca’s presentation on the genetic abnormalities of patients diagnosed with MGUS or smoldering disease identifies those aberrations that can be seen prior to a myeloma diagnosis
Dr. Vij's presentation dealt with markers of immune function and immune modulation after the use of Velcade in the peri-transplant setting (treatment with Velcade before and after transplant)
Dr. Kumar’s presentation concerned the use of the free light chain (FLC) assay to assess disease and response to therapy, particularly in oligosecretory and non-secretory patients
back
print
related articles
Be the first to comment